Oncology & Cancer

First of new generation of cancer drugs granted European approval

A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has today become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. ...

page 3 from 3